Trial · NCT04893577
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
NCT04893577, Phase 2, Completed, University of Utah; results first posted 2025-10-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions. Trials, record NCT04893577. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04893577
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
- NCT number
- NCT04893577
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- University of Utah
- Conditions
- Herpes Simplex Oral
- Interventions
- EDTA, Abreva
- First posted
- 2021-05-19
- Last updated
- 2025-10-31
- Results first posted
- 2025-10-31
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration (Days) of Herpes Labialis Outbreak Until Healed | Up to 14 days per patient | We will measure the number of days until lesion is healed from start of lesion to lesion resolved. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Duration (Days) of Herpes Labialis Outbreak Until Healed | Up to 14 days per patient | days | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration (Days) of Herpes Labialis Outbreak Until Healed | Study Drug (EDTA Eye Drops) | 10.6 | Full Range 8 to 13 | days | |
| Duration (Days) of Herpes Labialis Outbreak Until Healed | Active Comparator (Abreva) | 8.25 | Full Range 3 to 14 | days |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Study Drug (EDTA Eye Drops) | 5 | |
| Overall Study | STARTED | Active Comparator (Abreva) | 5 | |
| Overall Study | COMPLETED | Study Drug (EDTA Eye Drops) | 5 | |
| Overall Study | COMPLETED | Active Comparator (Abreva) | 4 | |
| Overall Study | NOT COMPLETED | Study Drug (EDTA Eye Drops) | 0 | |
| Overall Study | NOT COMPLETED | Active Comparator (Abreva) | 1 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Burning during application of study drug | Skin and subcutaneous tissue disorders | Study Drug (EDTA Eye Drops) | 2 | 5 | 2 |
| other | Burning during application of study drug | Skin and subcutaneous tissue disorders | Active Comparator (Abreva) | 0 | 5 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Study Drug (EDTA Eye Drops) | 0 | 5 |
| Total, all-cause mortality | Active Comparator (Abreva) | 0 | 5 |
| Total, other adverse events | Study Drug (EDTA Eye Drops) | 2 | 5 |
| Total, other adverse events | Active Comparator (Abreva) | 0 | 5 |
| Total, serious adverse events | Study Drug (EDTA Eye Drops) | 0 | 5 |
| Total, serious adverse events | Active Comparator (Abreva) | 0 | 5 |
Source ClinicalTrials.gov
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Study Drug (EDTA Eye Drops) vs Active Comparator (Abreva): deaths from any cause | Trial comparisons |
| Study Drug (EDTA Eye Drops) vs Active Comparator (Abreva): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04893577
GET https://conductscience.org/api/trials/v1/NCT04893577/registered